HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecasts to 2025
Updated on : February 17, 2023
The global HLA typing for transplant market in terms of revenue was estimated to be worth $656 million in 2019 and is poised to reach $968 million by 2025, growing at a CAGR of 6.1% from 2019 to 2025. The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics.
The molecular assay technologies segment accounted for the largest share of the HLA typing for transplant market, by technology
The global market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.
The independence reference laboratories end-user segment accounted for the largest share of the HLA typing for transplant market
Based on end-user, the global market is segmented into independent reference laboratories, hospitals & transplant centers, and research laboratories & academic institutes. In 2019, independent reference laboratories accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the rapid modernization and automation of diagnostic laboratories, growing number of research & development activities outsourced by pharmaceutical & biotechnology companies to independent reference laboratories, and the growing number of organ transplantation procedures.
North America accounted for the largest share of the HLA typing for transplant market
North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies (includes HLA typing) among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America.
Some of the players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), Omixon (Hungary). An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the HLA typing for transplants market. Product launches were the most widely adopted growth strategies.
Thermo Fisher Scientific is the top player in the global HLA typing for the transplants market. The company offers various diagnostic imaging modalities and services for transplant diagnostic procedures (includes HLA typing) in the market. To sustain its leadership position and ensure its future growth, the company has been focusing on product launches, agreements, and collaborations. The company also tries to evaluate new, emerging, and complementary technologies to identify new product opportunities.
HLA Typing for Trnsplant Market Report Scope:
|
Report Metric |
Details |
|
Market size available for years |
2017–2025 |
|
Base year considered |
2018 |
|
Forecast period |
2019–2025 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product, technology, application, end-user, and region |
|
Geographies covered |
North America (US and Canada), Europe (Germany, France, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, Australia, India, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM), and the Middle East and Africa |
|
Companies covered |
Major players covered include Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), Omixon (Hungary), Becton, Dickinson, and Company (US), Fujirebio, Inc. (Japan), and TBG Diagnostics Ltd. (Australia) |
This research report categorizes the HLA typing for transplant market into the following segments and sub-segments:
By Technology
-
Molecular Assay Technologies
-
PCR-Based Molecular Assays
- Real-time PCR
- Sequence-specific Primer-PCR
- Sequence-specific Oligonucleotide-PCR
- Other PCR-based Molecular Assays
-
Sequencing-based Molecular Assays
- Sanger Sequencing
- Next-generation Sequencing
- Other Sequencing-based Molecular Assays
-
PCR-Based Molecular Assays
- Non-molecular Assay Technologies
By Product & Service
- Reagents & Consumables
- Instruments
- Software & Services
By Application
-
Diagnostic Applications
- Antibody Screening
- Chimerism Monitoring
- Others
- Research Applications
By End-User
- Independent Reference Laboratories
- Hospitals & Transplant Centers
- Research Laboratories & Academic Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Spain
- Italy
- RoE
-
Asia Pacific
- China
- Japan
- Australia
- South Korea
- India
- RoAPAC
-
Latin America
- Brazil
- Mexico
- RoLATAM
- Middle East and Africa
Key Questions Addressed by the Report:
- What are the growth opportunities related to the adoption of HLA typing for transplant products across significant regions in the future?
- Emerging countries show immense opportunities for the growth and adoption of HLA typing for transplant instruments, related reagents & consumables, and software. Will this scenario continue in the next five years?
- Where will the advancements in products offered by various companies take the industry in the mid- to long-term?
- What are the newest trends and advancements in the HLA typing for the transplants market?
Frequently Asked Questions (FAQs):
What is the size of HLA Typing Transplant Market ?
The HLA typing for the transplants market is projected to reach USD 968 million by 2025, growing at a CAGR of 6.7%.
What are the major growth factors of HLA Typing Transplant Market ?
The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics.
Who all are the prominent players of HLA Typing Transplant Market ?
Some of the players in the HLA typing for transplant market are Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), Omixon (Hungary). .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 21)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 24)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 33)
4 PREMIUM INSIGHTS (Page No. - 37)
4.1 HLA TYPING FOR TRANSPLANT MARKET OVERVIEW
4.2 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY
4.3 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION
4.4 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019
4.5 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE
4.6 HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY
5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 KEY MARKET DRIVERS
5.2.1.1 Increasing number of transplant procedures
5.2.1.2 Technological advancements in the field of HLA typing
5.2.1.3 Increasing public-private funding for target research activities
5.2.2 KEY MARKET RESTRAINTS
5.2.2.1 High costs of molecular tests used for HLA typing procedures
5.2.2.2 Limited reimbursements for target procedures
5.2.3 KEY MARKET OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation
5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
5.2.3.3 Increasing public awareness about organ donation and transplantation across emerging countries
5.2.4 KEY MARKET CHALLENGES
5.2.4.1 Significant gap between the number of organ donors and organs required annually
6 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE (Page No. - 50)
6.1 INTRODUCTION
6.2 REAGENTS & CONSUMABLES
6.2.1 INCREASING PATIENT EMPHASIS ON EFFECTIVE PATIENT PROFILING DURING ORGAN TRANSPLANTATION TO DRIVE MARKET GROWTH
6.3 INSTRUMENTS
6.3.1 INCREASING PATIENT AWARENESS ABOUT THE BENEFITS OFFERED BY GENOME-BASED PROFILING WILL SUPPORT MARKET GROWTH
6.4 SOFTWARE & SERVICES
6.4.1 RISING DEMAND FOR INNOVATIVE HLA TYPING SOFTWARE DURING THE DETECTION OF SPECIFIC ALLELES IS SUPPORTING MARKET GROWTH
7 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY (Page No. - 55)
7.1 INTRODUCTION
7.2 MOLECULAR ASSAY TECHNOLOGIES
7.2.1 PCR-BASED MOLECULAR ASSAYS
7.2.1.1 Sequence-specific oligonucleotide-PCR
7.2.1.1.1 Growing awareness about the benefits offered by SSO-PCR among medical professionals to drive market growth
7.2.1.2 Sequence-specific primer-PCR
7.2.1.2.1 Growing public-private investments for research activities to support market growth
7.2.1.3 Real-time PCR
7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
7.2.1.4 Other PCR-based molecular assays
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
7.2.2.1 Sanger sequencing
7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market growth
7.2.2.2 Next-generation sequencing
7.2.2.2.1 Expansion in the application horizons of NGS in the field of tissue typing to support market growth
7.2.2.3 Other sequencing-based molecular assays
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED HLA TYPING PROCEDURES IS EXPECTED TO HAMPER MARKET GROWTH
8 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION (Page No. - 73)
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 ANTIBODY SCREENING
8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
8.2.2 CHIMERISM MONITORING
8.2.2.1 Rising trend of personalized transplant medicine for effective post-procedural clinical risk management to drive market growth
8.2.3 OTHER APPLICATIONS
8.3 RESEARCH APPLICATIONS
8.3.1 INCREASING IDENTIFICATION OF NEW GENES & BIOMARKERS IN DONOR-RECIPIENT CROSS MATCH WILL DRIVE THE MARKET GROWTH
9 HLA TYPING FOR TRANSPLANT MARKET, BY END USER (Page No. - 79)
9.1 INTRODUCTION
9.2 INDEPENDENT REFERENCE LABORATORIES
9.2.1 INCREASING NUMBER OF PREVENTIVE GENOMIC CLINICS TO DRIVE MARKET GROWTH
9.3 HOSPITALS & TRANSPLANT CENTERS
9.3.1 HEALTHCARE CONSOLIDATION AND ESTABLISHMENT OF NEW HOSPITALS TO SUPPORT MARKET GROWTH
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
9.4.1 GROWING AWARENESS ABOUT THE RESEARCH APPLICATIONS IN TRANSPLANT REJECTION MONITORING TO DRIVE MARKET GROWTH
10 HLA TYPING FOR TRANSPLANT MARKET, BY REGION (Page No. - 84)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Ongoing technological advancements in the field of HLA typing to drive market growth in the US
10.2.2 CANADA
10.2.2.1 Growing availability of HLA typing products to support market growth in Canada
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Germany accounted for the largest share of the European market
10.3.2 UK
10.3.2.1 Rising number of transplantation procedures to drive market growth in the UK
10.3.3 FRANCE
10.3.3.1 Adoption of molecular diagnostic techniques for donor-recipient compatibility testing is increasing in France
10.3.4 ITALY
10.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain market growth
10.3.5 SPAIN
10.3.5.1 Rising number of solid organ transplantation procedures to drive market growth in Spain
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.1.1 Significant growth in chronic disease prevalence to support market growth in Japan
10.4.2 CHINA
10.4.2.1 Healthcare infrastructure improvements to support market growth in China
10.4.3 INDIA
10.4.3.1 Increasing number of transplantation procedures to drive market growth in India
10.4.4 AUSTRALIA
10.4.4.1 Rising number of solid organ transplantation procedures to support market growth in Australia
10.4.5 SOUTH KOREA
10.4.5.1 Government initiatives to introduce medical coverage for transplantation to support market growth in South Korea
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Brazil accounted for the largest share of the LATAM market
10.5.2 MEXICO
10.5.2.1 Rising medical tourism to support market growth in Mexico
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST AND AFRICA
11 COMPETITIVE LANDSCAPE (Page No. - 130)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SCENARIO
11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS
11.3.2 KEY AGREEMENTS AND COLLABORATIONS
11.3.3 KEY ACQUISITIONS
11.3.4 KEY EXPANSIONS
11.4 COMPETITIVE LEADERSHIP MAPPING
11.4.1 VISIONARY LEADERS
11.4.2 INNOVATORS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES
12 COMPANY PROFILES (Page No. - 136)
12.1 THERMO FISHER SCIENTIFIC
12.1.1 BUSINESS OVERVIEW
12.1.2 PRODUCTS OFFERED
12.1.3 RECENT DEVELOPMENTS (2015–2019)
12.1.4 RECENT DEVELOPMENTS (2015–2019)
12.2 F. HOFFMAN-LA ROCHE LIMITED
12.2.1 BUSINESS OVERVIEW
12.2.2 PRODUCTS OFFERED
12.3 QIAGEN
12.3.1 BUSINESS OVERVIEW
12.3.2 PRODUCTS OFFERED
12.3.3 RECENT DEVELOPMENTS (2015–2019)
12.3.4 MNM VIEW
12.4 IMMUCOR
12.4.1 BUSINESS OVERVIEW
12.4.2 PRODUCTS OFFERED
12.4.3 RECENT DEVELOPMENTS (2015–2019)
12.5 ABBOTT LABORATORIES INC.
12.5.1 BUSINESS OVERVIEW
12.5.2 PRODUCTS OFFERED
12.6 CAREDX, INC.
12.6.1 BUSINESS OVERVIEW
12.6.2 PRODUCTS OFFERED
12.6.3 RECENT DEVELOPMENTS (2016–2019)
12.7 ILLUMINA
12.7.1 BUSINESS OVERVIEW
12.7.2 PRODUCTS & SERVICES OFFERED
12.7.3 RECENT DEVELOPMENTS (2015–2019)
12.7.4 MNM VIEW
12.8 BIO-RAD LABORATORIES
12.8.1 BUSINESS OVERVIEW
12.8.2 PRODUCTS OFFERED
12.9 ALPHA BIOTECH, LTD.
12.9.1 BUSINESS OVERVIEW
12.9.2 PRODUCTS OFFERED
12.10 GENDX
12.10.1 BUSINESS OVERVIEW
12.10.2 PRODUCTS & SERVICES OFFERED
12.10.3 RECENT DEVELOPMENTS (2015–2019)
12.11 LUMINEX
12.11.1 BUSINESS OVERVIEW
12.11.2 PRODUCTS OFFERED
12.11.3 RECENT DEVELOPMENTS (2015–2019)
12.12 BIOFORTUNA
12.12.1 BUSINESS OVERVIEW
12.12.2 PRODUCTS OFFERED
12.12.3 RECENT DEVELOPMENTS (2015–2019)
12.13 OMIXON
12.13.1 BUSINESS OVERVIEW
12.13.2 PRODUCTS OFFERED
12.13.3 RECENT DEVELOPMENTS (2015–2019)
12.14 CREATIVE BIOLABS
12.14.1 BUSINESS OVERVIEW
12.14.2 PRODUCTS OFFERED
12.15 TBG DIAGNOSTICS LIMITED
12.15.1 BUSINESS OVERVIEW
12.15.2 PRODUCTS OFFERED
12.15.3 RECENT DEVELOPMENTS (2015–2019)
12.16 OTHER COMPANIES
12.16.1 BAG HEALTHCARE
12.16.2 TAKARA BIO
12.16.3 HISTOGENETICS LLC
12.16.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.5 HANSA BIOPHARMA AB
13 APPENDIX (Page No. - 180)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES (141 Tables)
TABLE 1 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS FOR TRANSPLANT PROCEDURES, 2015–2018
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)
TABLE 3 APPLICABLE CODES FOR HLA TYPING
TABLE 4 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 5 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 6 INSTRUMENTS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 7 SOFTWARE & SERVICES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 9 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 10 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 11 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 12 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 13 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 14 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 15 PCR-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 16 PCR-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 17 PCR-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 18 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 19 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 20 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 21 REAL-TIME PCR MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 22 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 23 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 24 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 25 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 26 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 27 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 28 SANGER SEQUENCING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 29 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 30 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 31 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
TABLE 32 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 33 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 34 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 35 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 36 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 37 DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 38 ANTIBODY SCREENING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 39 CHIMERISM MONITORING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 40 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 41 RESEARCH APPLICATIONS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 43 INDEPENDENT REFERENCE LABORATORIES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 44 HOSPITALS & TRANSPLANT CENTERS MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 45 RESEARCH LABORATORIES & ACADEMIC INSTITUTES MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 46 HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 47 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 48 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 49 NORTH AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 54 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 55 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 56 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 57 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 58 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 59 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 60 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 61 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 62 EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 63 EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 67 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN GERMANY, 2015 VS. 2018
TABLE 68 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 71 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN THE UK, 2015 VS. 2018
TABLE 72 UK: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 73 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 74 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 75 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN FRANCE, 2015 VS. 2018
TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 77 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 78 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 79 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN ITALY, 2015 VS. 2018
TABLE 80 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 81 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 82 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 83 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN SPAIN, 2015 VS. 2018
TABLE 84 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 85 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 86 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 87 ROE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 88 ROE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 89 ROE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 90 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 91 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 92 ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 93 ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 96 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 97 JAPAN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 98 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 99 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 100 NUMBER OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CHINA, 2013 VS. 2015
TABLE 101 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 102 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 103 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 104 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN INDIA, 2015 VS. 2018
TABLE 105 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 106 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 107 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 108 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN AUSTRALIA, 2015 VS. 2018
TABLE 109 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 113 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 114 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 115 ROAPAC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 116 ROAPAC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 117 ROAPAC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 118 LATAM: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 119 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 120 LATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 121 LATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 122 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 123 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 124 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 125 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN BRAZIL, 2015 VS. 2018
TABLE 126 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 127 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 128 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 129 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN MEXICO, 2015 VS. 2018
TABLE 130 MEXICO: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 131 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 132 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 133 ROLATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 134 ROLATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 135 ROLATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 136 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 137 MEA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 138 MEA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017–2025 (USD MILLION)
TABLE 139 MEA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 140 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 141 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017–2025 (USD MILLION)
LIST OF FIGURES (36 Figures)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING FOR TRANSPLANT MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 HLA TYPING FOR TRANSPLANT MARKET SHARE, BY PRODUCT & SERVICE, 2019 VS. 2025
FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION)
FIGURE 8 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION)
FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION)
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE HLA TYPING FOR TRANSPLANT MARKET
FIGURE 11 INCREASING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
FIGURE 12 PCR-BASED MOLECULAR ASSAYS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
FIGURE 13 ANTIBODY SCREENING AND CHIMERISM MONITORING SEGMENTS TO WITNESS HIGH GROWTH IN THE ASIA PACIFIC MARKET
FIGURE 14 INDEPENDENT REFERENCE LABORATORIES ARE THE LARGEST END USERS IN THE APAC MARKET
FIGURE 15 NORTH AMERICA IS ESTIMATED TO BE THE LARGEST MARKET FOR ALL PRODUCT & SERVICE SEGMENTS IN THE HLA TYPING FOR TRANSPLANTS MARKET IN 2019
FIGURE 16 MARKET IN CHINA AND INDIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 17 HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
FIGURE 19 SOLID ORGAN TRANSPLANTATIONS PERFORMED IN THE US, 2015–2019
FIGURE 20 SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CANADA, 2015–2018
FIGURE 21 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
FIGURE 22 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
FIGURE 23 NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN JAPAN, 2015–2018
FIGURE 24 PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019
FIGURE 25 THERMO FISHER SCIENTIFIC DOMINATES THE GLOBAL HLA TYPING FOR TRANSPLANTS MARKET, AS OF 2019
FIGURE 26 HLA TYPING FOR TRANSPLANT MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 27 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 28 F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 29 QIAGEN: COMPANY SNAPSHOT (2018)
FIGURE 30 IMMUCOR: COMPANY SNAPSHOT (2016)
FIGURE 31 ABBOTT LABORATORIES INC.: COMPANY SNAPSHOT (2018)
FIGURE 32 CAREDX: COMPANY SNAPSHOT (2018)
FIGURE 33 ILLUMINA: COMPANY SNAPSHOT (2018)
FIGURE 34 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)
FIGURE 35 LUMINEX: COMPANY SNAPSHOT (2018)
FIGURE 36 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)
The study involved four major activities in estimating the current size of the HLA typing for the transplants market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva) were referred to identify and collect information for this study.
Primary Research
The HLA typing for transplants market comprises several stakeholders such as original equipment manufacturers (OEMs), product distributors and channel partners, hospitals and transplant centers, emergency care units and trauma centers, diagnostic laboratories, contract manufacturers and third-party suppliers, research laboratories and academic institutes, clinical research organizations (CROs), government and non-governmental regulatory authorities, and market research and consulting firms. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
A detailed market estimation approach was followed to estimate and validate the value of the HLA typing for the transplants market and other dependent submarkets, as mentioned below.
- Key players in the global HLA typing for transplants market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology included the study of the annual and quarterly financial reports & regulatory filings of significant market players as well as interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global HLA typing for the transplants market were determined using secondary sources and verified through primary sources.
- All key macro indicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the validated and verified quantitative & qualitative data.
- The gathered market data was consolidated and added to detailed inputs, analyzed, and presented in this report.
Data Triangulation
After arriving at the overall market size of the global HLA typing for the transplants market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for critical segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both the demand- and supply-side participants.
Report Objectives
- To define, describe, and forecast the HLA typing for transplants market based on product, technology, application, transplant type, end-user, and region
- To provide detailed information on the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and their contributions to the overall HLA typing for transplants market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the market value of various segments and subsegments for five regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the HLA typing for transplants market and comprehensively analyze their global revenue shares and core competencies
- To track and analyze competitive market-specific developments such as product launches/approvals and enhancements; partnerships, collaborations, agreements; expansions; and acquisitions
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of the five major companies
- Company Information: Detailed analysis and profiling of additional market players (Up to 5)
Growth opportunities and latent adjacency in HLA Typing for Transplant Market